课题基金 / 基金详情

A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3

A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3
立体定向消融放射治疗 (SABR) 综合治疗寡转移性（1-3 个转移）癌症的 III 期随机对照试验和经济评价：SABR-COMET-3
批准号：
409329
负责人：
Olson Robert A
金额：
$50.95万
依托单位：
BC Cancer, part of PHSA (Centre for the North)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2019
资助国家：
加拿大
项目状态：
未结题
起止时间：
2019-09-01 至 2025-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=409329&lang=en
关键词：
Biomarkers Cost-Effectiveness/Cost-Utility Metastatic Cancers Oligometastatic Disease/State Overall Survival Progression-Free Survival Quality Of Life Quality-Adjusted Life Years Stereotactic Radiotherapy Toxicity

项目摘要

项目成果

Olson Robert A的其他基金

相关文献

中文摘要
翻译
虽然全身治疗，如化疗，一直是转移性癌症(即已扩散到远处器官，如肺、肝、脑或骨的癌症)的主要治疗方法，但有新的证据表明，消融性治疗(如手术或
英文摘要
While systemic therapy, such as chemotherapy, has been the mainstay of treatment for metastatic cancer (i.e. cancer that has spread to distant organs such as lung, liver, brain, or bone), there is emerging evidence that ablative treatment (e.g. surgery or
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Future of Stereotactic Ablative Radiotherapy (SABR) Trials in Oligometastatic Cancer: Continuing Canadian-Led International Investigations in Radiation Therapy
  • 批准号：
    461060
  • 项目类别：
    Miscellaneous Programs
  • 资助金额：
    $0.73万
  • 财政年份：
    2022
  • 负责人：
    Olson Robert A
  • 依托单位：
    University of British Columbia